Asia Deal Watch: Daiichi Sankyo Licenses Glycotope's Gatipotuzumab ADC
Daiichi Sankyo gains worldwide rights to an antibody-drug conjugate version of Glycotope’s gatipotuzumab for various cancers. Also, Tasly buys China rights to Mesoblast's CV candidates and India's Cipla grows in Africa.
